Lipitor Lawsuit Update: New Case Management Order Issued in Lipitor Diabetes Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating Lipitor Lawsuits on behalf of patients who developed new-onset Type 2 diabetes, allegedly due to Lipitor.

Free Case Review
Our Firm hears from alleged victims of Lipitor and diabetes on a regular basis. We are pleased to see the federal Lipitor lawsuits moving forward.

Lipitor lawsuits ( that allege the use of the cholesterol-lowering statin caused patients to develop new-onset Type 2 diabetes continue to move forward in the federal multidistrict litigation underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to a Case Management Order issued on March 28, 2014, the Court is preparing to select attorneys to serve in various leadership roles in the proceeding, including the Plaintiffs’ Steering Committee. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)

“Our Firm hears from alleged victims of Lipitor and diabetes on a regular basis. We are pleased to see the federal Lipitor lawsuits moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have been harmed by this medication.

Lipitor Diabetes Allegations
Court documents indicate that at least 270 Lipitor lawsuits have been filed in the proceeding underway in the District of South Carolina. All of the complaints allege that Lipitor caused otherwise healthy patients to develop Type 2 diabetes, and claim that Pfizer Inc. was aware of this risk, but concealed this information in order to protect sales of the statin. Plaintiffs further allege that they would never have used Lipitor had Pfizer provided adequate warnings regarding the association with Lipitor and diabetes.

Court records indicate that the Lipitor diabetes litigation began to grow after the U.S. Food & Drug Administration (FDA) announced in February 2012 that it had asked the manufacturers of statins to add new information to their product labels regarding a possible increased risk of Type 2 diabetes. The action was prompted by a study published in JAMA: Internal Medicine in January 2012 that reported that post-menopausal women treated with drugs like Lipitor were at increased risk of developing new-onset Type 2 diabetes. * However, plaintiffs in Lipitor lawsuits claim that the warnings added to the drug’s label by Pfizer following the FDA’s 2012 mandate remain inadequate.

Individuals who allegedly developed Type 2 diabetes due to Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website